TMCnet News

Zimmer Biomet Publishes 2023 Sustainability Report
[May 06, 2024]

Zimmer Biomet Publishes 2023 Sustainability Report

Sustainability report highlights progress in product quality and safety, environmental and greenhouse gas emissions goals, and team member engagement and development

WARSAW, Ind., May 6, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today published its 2023 Sustainability Report which provides an overview of the company's environmental, social and governance (ESG) program, progress, and accomplishments. The report outlines Zimmer Biomet's formal commitment with Science Based Targets initiative (SBTi) to reach Net-Zero greenhouse gas (GHG) emissions by 2050 and aligns with the Sustainability Accounting Standards Board (SASB) framework and the Task Force on Climate-related Financial Disclosures (TCFD).

As detailed in the report, Zimmer Biomet is committed to being a good corporate citizen and a leader in responsible, ethical business practices. Key highlights include:

  • Achieving the highest ever employee engagement levels since our 2015 merger. Our company-wide engagement index score increased a remarkable 7 points over 2022 results, with improved scores for 100% of the indicators.
  • Furthering our commitment to integrating health equity into our business strategy. Our new Community Centered Care (C3) framework aims to increase patient access to quality care within underserved communities. The framework implements a multi-pronged approach that engages the health network to collaborate on insights and innovation to improve patient outcomes.
  • Continuing to make progress toward reaching our SBTi-approved goals of reducing carbon emissions. We reduced our 2023 Scope 1 and 2 (market-based) carbon emissions by more than 7% from our 2022 levels.  Additionally, Zimmer Biomet is working with suppliers to increase transparency and improve environmental performance. 
  • Expanding Zero Waste to Landfill (ZWTL) initiative. The flagship program aims to have no waste sent directly to landfill for disposal. In 2023, we moved this global initiative forward with 18 sites now internally certified, representing 60% of our in-scope global network.
  • Zero pending FDA Warning Letters as of December 2023. As part of our commitment to drive greater accountability for compliance with, and sustained improvements in, our global quality system, we cleared our single outstanding FDA Warning Letter in December 2023.
  • Continuing our focus on quality management programs and performance. For the second year in a row, Zimmer Biomet maintained fewer than 10 product recalls in the year.

Ivan Tornos, President and CEO of Zimmer Biomet, commented, "I am incredibly proud of the progress we made this year in advancing sustainability initiatives across all facets of our business. From reducing our carbon footprint and minimizing waste to increasing engagement within our workforce, we have achieved key milestones that demonstrate accountability and growth. Our Sustainability Report serves as a roadmap for our ongoing efforts to deliver value for our patients, customers and team members."

Find the full report on

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X / Twitter at

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.



Heather Zoumas-Lubeski 

Zach Weiner



[email protected]   

[email protected]

Cision View original content to download multimedia:

SOURCE Zimmer Biomet Holdings, Inc.

[ Back To's Homepage ]